文献速递MDS 与骨髓增殖性肿瘤

Jaktinib治疗未接受过Janus激酶抑制剂治疗的骨髓纤维化患者的安全性和有效性:一项II期试验结果

Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.
PubMed 文献 · Am J Hematol · 2022-10-04

这项II期试验纳入118例未接受过JAK抑制剂治疗的骨髓纤维化患者,分别接受jaktinib 100 mg每日两次或200 mg每日一次治疗。第24周时,100 mg每日两次组54.8%(34/62)和200 mg每日一次组31.3%(15/48)的患者达到脾脏体积缩小≥35%(SVR35,p=0.0199)。Jaktinib可缩小脾脏、改善贫血和其他临床症状,耐受性良好。

要点

  • 第24周SVR35:100 mg每日两次组54.8%(34/62)vs 200 mg每日一次组31.3%(15/48),p=0.0199。
  • 基线血红蛋白≤100 g/L者中35.6%(21/59)治疗后血红蛋白升高≥20 g/L。
  • 最常见的≥3级血液学治疗中出现的不良事件为贫血、血小板减少和中性粒细胞减少。

核心结论

  • Jaktinib可缩小脾脏、改善贫血和其他临床症状,且耐受性良好。

研究设计与样本

  • II期试验,2019年1月8日至2020年8月29日招募118例骨髓纤维化患者,接受jaktinib 100 mg每日两次或200 mg每日一次治疗。
  • 主要终点为第24周脾脏体积缩小≥35%(SVR35)的患者比例。
  • 次要终点包括贫血改善、症状缓解率和安全性特征。

主要发现

  • 第24周SVR35:100 mg每日两次组54.8%(34/62)vs 200 mg每日一次组31.3%(15/48),p=0.0199。
  • 基线血红蛋白≤100 g/L的患者中,35.6%(21/59)治疗后血红蛋白升高至≥20 g/L。
  • 第24周总症状评分改善≥50%的患者比例:每日两次组69.6%(39/56)vs 每日一次组57.5%(23/40)。
  • 最常见的≥3级血液学治疗中出现的不良事件(≥10%)为贫血(100 mg每日两次组24.2%,200 mg每日一次组28.8%)、血小板减少(16.7%,11.5%)和中性粒细胞减少(3.0%,11.5%)。
  • 所有非血液学治疗中出现的不良事件均为轻度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelofibrosis (MF) is associated with several constitutional symptoms. Currently, there are few therapeutic options for MF. Jaktinib, a novel, small-molecule inhibitor of JAK, is currently being studied for its potential to treat MF. This phase 2 trial investigated efficacy and safety of jaktinib in the treatment of MF patients. The primary end point was the proportion of patients with ≥35% reduction in spleen volume (SVR35, proportion of patients with ≥35% reduction in spleen volume) at week 24. The secondary end points included improvement of anemia, rates of symptom response, and safety profile. Between January 8, 2019 and August 29, 2020, 118 patients were recruited and treated with either jaktinib 100 mg BID or 200 mg QD. At week 24, 54.8% (34/62) of patients in the 100 mg BID group and 31.3% (15/48) in the 200 mg QD group achieved SVR35 (p = .0199). Jaktinib treatment increased hemoglobin level to ≥20 g/L in 35.6% (21/59) of patients with hemoglobin ≤100 g/L at baseline. The proportion of patients who achieved a ≥50% improvement in total symptom score at week 24 was 69.6% (39/56) in the BID group and 57.5% (23/40) in the QD group. The most common ≥ grade 3 hematological treatment-emergent adverse events (TEAEs; ≥ 10%) were anemia (100 mg BID: 24.2%, 200 mg QD: 28.8%), thrombocytopenia (16.7%, 11.5%), and neutropenia (3.0%, 11.5%). All non-hematological TEAEs were mild. These results indicate that jaktinib can shrink the spleen, improve anemia, and other clinical symptoms with good tolerability.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhou H, Jiang Z, et al. Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial. Am J Hematol. 2022. PMID: 36054786. doi:10.1002/ajh.26709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。